ClinicalTrials.gg
RecruitingNCT07564154Updated Aug 11, 2026

A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA)

A Phase 1 interventional study of KT502 in Rheumatoid Arthritis (RA), sponsored by Kali Therapeutics, Inc.. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Kali Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 154 studies in Arthritis, Rheumatoid with a site in Australia — 16 open to participants now, 21 under way, 3 of them phase 3. Arthritis, Rheumatoid · Australia.

Planned enrollment
131st of 140
27 · median 469
Started
2026
with 8 others
Phase 1
21 of 154
12 open now
Primary completion
2027-12
later than 9 of 20 live
Registered
152nd of 154
by date

Among the 154 studies in Arthritis, Rheumatoid with a site in Australia, this one is the 131st largest by planned enrollment of the 140 interventional ones that give a count, is one of 9 that started in 2026, is one of 21 in phase 1, reaches primary completion later than 9 of the 20 other live ones, and was the 152nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

16 of the 154 studies in Arthritis, Rheumatoid with a site in Australia are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Arthritis, Rheumatoid with a site in Australia, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT502 administered subcutaneously to participants with Rheumatoid Arthritis (RA). The study will have 2 parts: Part A is a single ascending dose finding (SAD) and Part B is dose escalation by fractionated dosing.

03

Conditions studied

  • Rheumatoid Arthritis (RA)

Keywords

  • Rheumatoid Arthritis (RA)
  • T-Cell Engagers (TCEs)
  • B-Cell Depletion
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 75 years old
  2. Diagnosis of adult-onset RA for at least 6 months
  3. Moderately to severely active RA
  4. Inadequate treatment response as defined in the protocol
  5. RF + or ACPA+
  6. Stable use of traditional DMARDs is permitted
  7. Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.

Exclusion criteria

Exclusion:

  1. Functional class IV as defined by the ACR Classification of Functional Status in RA
  2. Presence of any concomitant disease other than RA
  3. Active infection, history of serious recurrent or chronic infection
  4. History of progressive multifocal leukoencephalopathy
  5. Have a diagnosis or history of malignant disease within 5 years or breast cancer diagnosed within the previous 10 years.
  6. History of or planned organ transplant and/or or allogeneic hematopoietic stem cell transplantation
  7. Receipt of within 4 weeks
  8. Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after study
  9. Women who are pregnant or breastfeeding
  10. Significant or uncontrolled medical disease that would preclude participant participation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Part A (SAD): Non-Fractionated Single Ascending Doses / Dose Finding

    Participants will receive a KT502 Subcutaneous Injection at an assigned dose as on Day 1

    Drug: KT502

  • Experimental
    Part B: Fractionated Dosing / Dose Escalation

    Participants will receive a KT502 Subcutaneous Injection as a step-up/fractionated dosing on Day 1 and Day 8

    Drug: KT502

Interventions

  • DrugKT502

    KT502 is a monoclonal antibody that depletes B cells by targeting CD19 and CD3

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Incidence and severity of Adverse Events, including DLTs, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

    Time frame: From Baseline Up to 12 weeks

  2. Incidence of Cytokine-release Syndrome (CRS)

    Incidence and severity of CRS with severity determined according to the 2019 American Society for Transplantation and Cellular Therapy (ASTCT) CRS Consensus grading criteria

    Time frame: From Baseline Up to 12 Weeks

  3. Changes in Pulse Rate from Baseline

    Vital signs: Changes in Pulse Rate from Baseline

    Time frame: From Baseline Up to 12 Weeks

  4. Changes in Respiratory Rate from Baseline

    Vital Signs: Changes in Respiratory Rate from Baseline

    Time frame: From Baseline to 12 Weeks

  5. Changes in Blood Pressure from Baseline

    Vital Signs: Changes in Blood Pressure from Baseline

    Time frame: Baseline to 12 Weeks

  6. Changes in Temperature from Baseline

    Vital Signs: Changes in Body Temperature from Baseline

    Time frame: Baseline to 12 Weeks

  7. Changes in Hematology Clinical Laboratory Results from Baseline

    Hematology: Changes in results from Baseline

    Time frame: From Baseline Up to 12 Weeks

  8. Changes in Chemistry Clinical Laboratory Results from Baseline

    Chemistry: Changes in results from Baseline

    Time frame: From Baseline Up to 12 Weeks

  9. Changes in Urinalysis Clinical Laboratory Results from Baseline

    Urinalysis: Changes in results from Baseline

    Time frame: Baseline Up to 12 Weeks

  10. Changes in Coagulation Clinical Laboratory Results from Baseline

    Coagulation: Changes in results from Baseline

    Time frame: From Baseline Up to 12 Weeks

  11. ECG

    Change from baseline in 12-lead electrocardiogram (ECG)

    Time frame: From Baseline to 12 Weeks

Secondary outcomes

  1. Serum Concentrations of KT502

    Blood samples will be collected at specific time points for calculating serum concentrations of KT502

    Time frame: Part A: Pre-dose; Day 2, 3, 8, 15, 29 Part B (1st Dose): Pre-dose, Day 2, 3 Part B (2nd Dose): Pre-dose Day 8; Day 9, 10, 11, 15, 29, 43, 57 and 85

  2. Incidence of Treatment-induced Anti-Drug Antibodies (ADAs)

    Immunogenicity: Incidence of participants with treatment induced Anti-Drug Antibodies (ADA)

    Time frame: Part A: Pre-dose; Day 8, 15, 22, 29, 43, 57 and 85 Part B (1st Dose): Pre-dose Part B (2nd Dose): Pre-dose Day 8; Day 11, 15, 22, 29, 43, 57 and 85

  3. To Determine Cmax

    Maximum observed serum KT502 concentration

    Time frame: Day 1 - Day 85

  4. To Determine Tmax, Derived from Serum Concentration of each Dose of KT502

    Time to maximum observed concentration

    Time frame: Day 1 - Day 85

  5. Area Under the Serum-concentration Time Curve (AUC) from Time Zero to the Last Timepoint with Measurable Analyte Concentration (AUC0-t)

    Area under the concentration-time curve from 0 to the time of the last quantifiable concentration (AUClast)

    Time frame: Day 1 - Day 85

  6. AUC from Time Zero to Infinity (AUCinf)

    Area under the plasma concentration versus time curve (AUC) from time 0 extrapolated to infinity

    Time frame: Day 1 - Day 85

  7. To Determine Terminal Half-Life (T1/2)

    Terminal elimination half-life summarized by dosing regimen

    Time frame: Day 1 - Day 85

  8. Total Body Clearance (CL/F)

    CL is the measure of the rate at which a drug is metabolized or eliminated by normal biological processes

    Time frame: Day 1 - Day 85

  9. Volume of Distribution During the Terminal Phase (Vz/F)

    Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug

    Time frame: Day 1 - Day 85

  10. Change in Levels of B Cell Count

    Pharmacodynamics: Change in levels of B cell counts measured at specific timepoints

    Time frame: Screening; Day 1 - Day 85

  11. Duration of B Cell Depletion

    Pharmacodynamics: The duration of B cell depletion measured from Baseline

    Time frame: Day 1 - Day 85

  12. Change in Levels of Acute Inflammatory Markers

    Pharmacodynamics: Change in levels of acute Inflammatory markers (C-reactive protein (CRP) and CRS-related cytokines at specific timepoints

    Time frame: Pre-dose; Day 2, 3, 4, 5, 8, 9, 10, 15, 22, 29, 43, 57 and 85

07

Study locations

2 of 2 sites recruiting
  • Kali Therapeutics Trial Site
    Bayswater, Victoria, Australia
    Recruiting
  • Kali Therapeutics Trial Site
    Auckland, NZ, New Zealand
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — This is a Phase 1 trial.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 17 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 4, 2026
StartActual
Jul 13, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Jul 2028
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07564154
Lead sponsor
Kali Therapeutics, Inc.
Responsible party
Sponsor
First posted
May 4, 2026
Start date
Jul 13, 2026
Primary completion
Dec 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Aug 11, 2026

Study contacts

Trial Information
Contact
clinical@kalitherapeutics.com
1-858-888-3080

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion